{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=87", "query": { "condition": "Advanced Solid Neoplasm", "page": 87 }, "page_size": 10 }, "pagination": { "page": 87, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=88&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=86&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T20:24:53.987Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06917079", "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "NSCLC", "PDAC - Pancreatic Ductal Adenocarcinoma", "CRC (Colorectal Cancer)", "Metastatic Non-Small Lung Cell Cancer", "Metastatic Colorectal Cancer (CRC)", "KRAS G12A", "KRAS G12C", "KRAS G12D", "KRAS G12S", "KRAS G12V", "Metastatic Pancreatic Ductal Adenocarcinoma", "Advanced Lung Carcinoma", "Solid Tumor, Adult" ], "interventions": [ { "name": "BBO-11818", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum chemotherapy (cisplatin or carboplatin)", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "BBO-10203", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 665, "start_date": "2025-03-31", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 16, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06917079" }, { "nct_id": "NCT00420615", "title": "Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Patupilone and Omeprazole", "type": "DRUG" }, { "name": "Patupilone + Midalzolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420615" }, { "nct_id": "NCT02419417", "title": "Study of BMS-986158 in Subjects With Select Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Tumors" ], "interventions": [ { "name": "BMS-986158", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 83, "start_date": "2015-06-19", "completion_date": "2021-03-17", "has_results": true, "last_update_posted_date": "2022-06-16", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 6, "location_summary": "Duarte, California • Aurora, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419417" }, { "nct_id": "NCT03733990", "title": "A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "FP-1305 (bexmarilimab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Faron Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2018-12-03", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03733990" }, { "nct_id": "NCT02516813", "title": "Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "M3814 100 mg", "type": "DRUG" }, { "name": "M3814 200 mg", "type": "DRUG" }, { "name": "M3814 300 mg", "type": "DRUG" }, { "name": "M3814 400 mg", "type": "DRUG" }, { "name": "M3814 50 mg", "type": "DRUG" }, { "name": "Fractionated RT", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2015-09-15", "completion_date": "2021-11-19", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 9, "location_summary": "Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Billings", "state": "Montana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02516813" }, { "nct_id": "NCT03495323", "title": "A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "LY3300054", "type": "DRUG" }, { "name": "Prexasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-05-16", "completion_date": "2021-02-01", "has_results": false, "last_update_posted_date": "2021-04-15", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03495323" }, { "nct_id": "NCT04770246", "title": "TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations", "Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations" ], "interventions": [ { "name": "TAS-117", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-31", "completion_date": "2023-03-06", "has_results": false, "last_update_posted_date": "2024-09-04", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 5, "location_summary": "Santa Monica, California • New York, New York • Cleveland, Ohio + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04770246" }, { "nct_id": "NCT06265688", "title": "First In Human Study of CX-2051 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "CX-2051", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2024-04-02", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 8, "location_summary": "Denver, Colorado • Boston, Massachusetts • The Bronx, New York + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265688" }, { "nct_id": "NCT00544596", "title": "R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "R-(-)-gossypol acetic acid", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2007-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 4, "location_summary": "Sioux Falls, South Dakota • La Crosse, Wisconsin • Madison, Wisconsin", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "La Crosse", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544596" }, { "nct_id": "NCT05932862", "title": "A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "XL309", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 429, "start_date": "2024-04-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-14T20:24:53.987Z", "location_count": 13, "location_summary": "Jacksonville, Florida • Orlando, Florida • Tampa, Florida + 10 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05932862" } ] }